Key facts
- It has raised $1.0M; the latest was Seed Round ($1.0M) in Jun 2025.
- Notable investors include Leiden University, Libertatis Ergo Holding (LEH), UNIIQ, unlock_.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for GenLumina (Drug Discovery)
- ·The full record, as it builds
Funding rounds
No funding rounds for GenLumina (Drug Discovery) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About GenLumina (Drug Discovery)
Developer of a DNA nanotechnology and light-activated drugs intended to transform cancer treatment and eliminate cancer. The company specializes in using light controlled treatment and nanocluster technology that kills cancer cells without damaging healthy tissue, providing oncology researchers and healthcare providers with a minimally invasive, highly targeted therapeutic approach that reduces side effects and improves treatment precision.
- Sector
- Healthcare
- HQ
- Leiden, Netherlands
- Founded
- 2024
- Employees
- 4
- Website
- genlumina.com/
- Ownership
- Privately Held (backing)
GenLumina (Drug Discovery) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in GenLumina (Drug Discovery) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on GenLumina (Drug Discovery) in its N-PORT filings yet. We sweep new filings monthly.